Form D · Biotechnology

SOLULINK Inc

San Diego, CA · CIK 0001374327

Offering snapshot reported Dec 2, 2013 · SEC filing

Reported sold
$430K
Offering amount: $430K
Investors reported
18
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Nov 22, 2013
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Dec 2, 2013Initial$430,000No comparison18SEC filing
Nov 21, 2011Initial$1,000,000No comparison20SEC filing
Mar 1, 2011Amendment$1,460,000$1,010,000vs Jan 28, 201026SEC filing
Jan 28, 2010Initial$450,000No comparison21SEC filing
Mar 10, 2008PaperNot reportedNo comparisonNot reportedSEC filing
Aug 29, 2006PaperNot reportedNo comparisonNot reportedSEC filing

Offering details

Securities
Debt, Option to acquire
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-207245

Source: Form D, filed Dec 2, 2013. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Jack Ball, Jr. Director, Executive
Steve De Graw Executive
Stephen De Graw Director, Executive
Mark Horne Director
Tim Mayleben Director
David Mc Carty Director, Executive
John Miller Director
Howard Sampson Director
David Schwartz Director, Executive
Walter Young, Jr. Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
9853 Pacific Heights Boulevard Suite H
San Diego, CA, 92121